跳转至内容
Merck
CN

SML3605

Sigma-Aldrich

Selexipag

≥98% (HPLC)

登录查看公司和协议定价

别名:
2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide, ACT-293987, NS-304
经验公式(希尔记法):
C26H32N4O4S
分子量:
496.62
MDL编号:
UNSPSC代码:
51111800
UNSPSC代码:
12352200
NACRES:
NA.21

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

-10 to -25°C

SMILES字符串

CC(C)N(CCCCOCC(NS(C)(=O)=O)=O)C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1

生化/生理作用

Selexipag is a potent, highly selective and orally available nonprostanoid agonist for the PGI2 receptor (IP receptor). Selexipag is readily hydrolyzed to the active metabolite ACT-333679 (MRE-269), which is also a potent and selective agonist at IP receptors. In contrast to the prostacyclin analogs iloprost and beraprost, selexipag and metabolite ACT-333679 does not contract gastric fundus up to mM concentrations.

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug
Journal of Pharmacology and Experimental Therapeutics, 322, 1181-1188 (2007)
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery
Journal of Pharmacology and Experimental Therapeutics, 326(3), 691-699 (2008)
Keith Morrison et al.
The Journal of pharmacology and experimental therapeutics, 335(1), 249-255 (2010-07-28)
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI(2)) receptor (IP receptor) agonist that is chemically distinct from PGI(2) and is in clinical development for the treatment of pulmonary arterial hypertension. Selexipag is highly selective for the human IP receptor in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门